Legislation in Brief
This article was originally published in The Gold Sheet
Executive Summary
The Senate user fee bill may get industry’s version of track-and-trace or FDA’s or neither, but certainly would free FDA from inspecting facilities every two years. Meanwhile, Congress keeps generating ideas for combating drug shortages.
You may also be interested in...
Track And Trace, EU Style: Firms Try Self-Administered System
European pharma trade federation issues a tender for its product coding system to fight counterfeits, as part of effort to convince the European Commission that a stakeholder-run initiative will work best.
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement
FDA says it likely will oppose the provision because it would create more administrative complexity and increase fees paid by individual firms, but many provider and professional associations think waivers could help prevent and alleviate drug shortages.
GMP Third-Party Audits Offered In Draft Senate User Fee Legislation
Bipartisan group of senators unveils several draft provisions of user fee legislation, including a program to allow third-party auditors to evaluate manufacturing facility compliance with U.S. standards for drugs.